Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Chlorogenic acid has demonstrated promising effects in the treatment of glycemic control, obesity, dyslipidemia, insulin secretion, among others. The above mentioned findings show that Chlorogenic acid has an excellent potential for the control of glucose as well as insulin secretion and insulin sensitivity.
A randomized, double-blind, placebo-controlled clinical trial was carried out in 30 patients with a diagnosis of impaired glucose tolerance in accordance with the American Diabetes Association criteria. The patients received 400 mg capsules of Chlorogenic acid or placebo, three times daily 1/ 2 hour before meals for 90 days. Before and after intervention the investigators evaluated: 2 hours plasma glucose, glycated hemoglobin (A1C), triglycerides, high-density lipoprotein, fasting glucose and blood pressure body weight, body mass index, waist circumference, total cholesterol, low-density lipoprotein, very-low-density lipoprotein, creatinine, aspartate transaminase and alanine transaminase.
Were calculated: Areas under the curve of glucose and insulin were calculated with de Trapezoidal formula. Total insulin secretion was evaluated with the Insulinogenic index and the insulin sensitivity was estimated using the Matsuda index.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days. |
|
| Chlorogenic acid | Experimental | 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | Placebo: 1200 mg per day for three months |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Fasting Plasma Glucose (FPG) | Reflect the fasting glucose level after a 10- to 12-h overnight fast. | Week 12. |
| 2 Hours Plasma Glucose (2-h PG) | Subjects underwent a 2-h oral glucose tolerance test (2-h OGTT) by consuming 75-g of a dextrose load, and one sample was obtained 120 min after glucose administration. | Week 12. |
| Glycated Hemoglobin A1c (A1C) | Shows what a person's average blood glucose level was for the 2 to 3 months before the test high-performance. | Week 12. |
| Total Insulin Secretion | After intervention. Total insulin secretion was calculated with the Insulinogenic index (Δ ABC insulin / Δ ABC glucose). | Week 12. |
| First Phase of Insulin Secretion | After intervention with Stumvoll index | Week 12. |
| Insulin Sensitivity | After intervention Matsuda Index | Week 12. |
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Curve of Glucose | Area under the curve of glucose was obtained using the trapezoidal integration. | Week 12. |
| Area Under the Curve of Insulin | Before and after intervention area under the curve of insulin |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Esperanza Martínez, PhD Science | University of Guadalajara | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara | Guadalajara | Jalisco | 44340 | Mexico |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16551305 | Background | van Popele NM, Elizabeth Hak A, Mattace-Raso FU, Bots ML, van der Kuip DA, Reneman RS, Hoeks AP, Hofman A, Grobbee DE, Witteman JC. Impaired fasting glucose is associated with increased arterial stiffness in elderly people without diabetes mellitus: the Rotterdam Study. J Am Geriatr Soc. 2006 Mar;54(3):397-404. doi: 10.1111/j.1532-5415.2005.00614.x. | |
| 10097917 |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days. Placebo: Placebo: 1200 mg per day for three months |
| FG001 | Chlorogenic Acid | 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days. Chlorogenic acid: Chologenic acid: 1200 mg per day for three months |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days. Placebo: Placebo: 1200 mg per day for three months |
| BG001 | Chlorogenic Acid |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Fasting Plasma Glucose (FPG) | Reflect the fasting glucose level after a 10- to 12-h overnight fast. | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Median | Standard Deviation | mmol/L | Week 12. |
|
Adverse events were collected thoughtout the 90 days of the study
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days. Placebo: Placebo: 1200 mg per day for three months |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrea | Gastrointestinal disorders | ANY | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dra. Esperanza Martínez Abundis | Institute of Experimental and Clinical Therapeutics | +52-33-10-58-52-00 | 34211 | esperanzamartnezabundi@yahoo.com |
Not provided
| ID | Term |
|---|---|
| D018149 | Glucose Intolerance |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D006943 | Hyperglycemia |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002726 | Chlorogenic Acid |
| ID | Term |
|---|---|
| D002934 | Cinnamates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Chlorogenic acid | Drug | Chologenic acid: 1200 mg per day for three months |
|
|
| Week 12. |
| Body Weight | The weight was measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12 | Week 12. |
| Body Mass Index | The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12 | Week 12. |
| Waist Circumference (WC) | Waist circumference was evaluated at baseline and at week 12 with a flexible tape and the entered values reflects the waist circumference measure at week 12 | Week 12. |
| Systolic Blood Pressure (SBP) | The Systolic Blood Pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12 | Week 12. |
| Diastolic Blood Plessure (DBP) | The Diastolic blood plessure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12 | Week 12. |
| Triglycerides (TG) | The triglycerides were evaluated at baseline and week 12 with enzymatic-colorimetric techniques and the entered values reflect the triglycerides level at week 12 | Week 12. |
| Total Cholesterol (TC) | The total cholesterol was estimated by standardized techniques at baseline and week 12 and the entered values reflect the total cholesterol level at week 12 | Week 12. |
| High-density Lipoprotein Cholesterol (HDL-C) | The HDL-C levels were evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the HDL-C level at week 12 | Week 12. |
| Low-density Lipoprotein Cholesterol (LDL-C) | The LDL-C levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the LDL-C levels at week 12 | Week 12. |
| Very-low Density Lipoprotein (VLDL) | The VLDL levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the c-LDL levels at week 12 | Week 12. |
| Glutamic Pyruvic Transaminase (GPT) | Before and after intervention by spectrophotometry | Week 12. |
| Glutamic Oxaloacetic Transaminase (GOT) | Before and after intervention by spectrophotometry | Week 12. |
| Creatinine | The creatinine levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the uric acid levels at week 12 | Week 12. |
| Uric Acid | The uric acid levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the creatinina levels at week 12. | Week 12. |
| Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care. 1999 Mar;22(3):399-402. doi: 10.2337/diacare.22.3.399. |
| 18996826 | Background | Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, Garvey WT, Gavin JR 3rd, Grunberger G, Horton ES, Jellinger PS, Jones KL, Lebovitz H, Levy P, McGuire DK, Moghissi ES, Nesto RW. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008 Oct;14(7):933-46. doi: 10.4158/EP.14.7.933. No abstract available. |
| 22079683 | Background | Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011 Dec;94(3):311-21. doi: 10.1016/j.diabres.2011.10.029. Epub 2011 Nov 12. |
| 23598536 | Background | Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH; American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr;19(2):327-36. doi: 10.4158/endp.19.2.a38267720403k242. No abstract available. |
| 18370832 | Background | Guerrero-Romero F, Rodriguez-Moran M, Perez-Fuentes R, Sanchez-Guillen MC, Gonzalez-Ortiz M, Martinez-Abundis E, Brito-Zurita O, Madero A, Figueroa B, Revilla-Monsalve C, Flores-Martinez SE, Islas-Andrade S, Rascon-Pacheco RA, Cruz M, Sanchez-Corona J. Prediabetes and its relationship with obesity in Mexican adults: The Mexican Diabetes Prevention (MexDiab) Study. Metab Syndr Relat Disord. 2008 Mar;6(1):15-23. doi: 10.1089/met.2007.0020. |
| 25897193 | Background | American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015 Apr;33(2):97-111. doi: 10.2337/diaclin.33.2.97. No abstract available. |
| 17364278 | Background | Adeney KL, Williams MA, Schiff MA, Qiu C, Sorensen TK. Coffee consumption and the risk of gestational diabetes mellitus. Acta Obstet Gynecol Scand. 2007;86(2):161-6. doi: 10.1080/00016340600994992. |
| 15694706 | Background | McCarty MF. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med Hypotheses. 2005;64(4):848-53. doi: 10.1016/j.mehy.2004.03.037. |
| 11208940 | Background | Olthof MR, Hollman PC, Katan MB. Chlorogenic acid and caffeic acid are absorbed in humans. J Nutr. 2001 Jan;131(1):66-71. doi: 10.1093/jn/131.1.66. |
| 24039147 | Background | Renouf M, Marmet C, Giuffrida F, Lepage M, Barron D, Beaumont M, Williamson G, Dionisi F. Dose-response plasma appearance of coffee chlorogenic and phenolic acids in adults. Mol Nutr Food Res. 2014 Feb;58(2):301-9. doi: 10.1002/mnfr.201300349. Epub 2013 Sep 4. |
| 40614321 | Derived | Zhu H, Chen J, Dong X, Qin X, Li Z. Influence of dihydrocaffeic acid and quinic acid on lung metabolism and function: Implications for dietary interventions. Biochem Biophys Res Commun. 2025 Sep 1;777:152274. doi: 10.1016/j.bbrc.2025.152274. Epub 2025 Jun 28. |
1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
Chlorogenic acid: Chologenic acid: 1200 mg per day for three months
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Body weight | Body weight was evaluated through a bioimpedance digital scale and results are reported in kg with a decimal. | Mean | Standard Deviation | kg |
|
| Body mass index | Mean | Standard Deviation | kg/m^2 |
|
| Waist circumference | Waist circumference was measured with a flexible tape in them id point between the lowest rib and the iliac crest and is expressed in centimeters. | Mean | Standard Deviation | cm |
|
| Systolic blood pressure | Blood pressure was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of diastolic blood pressure (DBP). The value was expressed on mmHg | Mean | Standard Deviation | mmHg |
|
| Diastolic blood pressure | Blood pressure was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of diastolic blood pressure (DBP). The value was expressed on mmHg. | Mean | Standard Deviation | mmHg |
|
| Fasting plasma glucose | The blood sample for determining of fasting plasma glucose (FPG), was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. | Mean | Standard Deviation | mmol/L |
|
| 2-hour plasma glucose | The blood sample for determining of 2-hour plasma glcuose (2-h PG), was taken two hours after the ingestion of the drink with 75 g dextrose and was evaluated by spectrophotometry method. The value was expressed on mmol/L. | Mean | Standard Deviation | mmol/L |
|
| Glycated hemoglobin A1c | Mean | Standard Deviation | Percent of glycated hemoglobin |
|
| Triglycerides | The blood sample for determining of triglycerides (TG), was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. | Mean | Standard Deviation | mmol/L |
|
| Total cholesterol | The blood sample for determining of total cholesterol (TC) , was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. | Mean | Standard Deviation | mmol/L |
|
| High-density lipoprotein cholesterol (HDL-C) | The blood sample for determining of HDL-C, was taken after an overnight fast and was evaluated by colorimetric method. The value was expressed on mmol/L. | Mean | Standard Deviation | mmol/L |
|
| Low-density lipoprotein cholesterol (LDL-C) | The blood sample for determining of LDL-C, was taken after an overnight fast and was calculated by Friedewald formula. The value was expressed on mmol/L. | Mean | Standard Deviation | mmol/L |
|
| Very low-density lipoprotein (VLDL) | Mean | Standard Deviation | mmol/L |
|
| Glutamic oxaloacetic transaminase (GOT) | Mean | Standard Deviation | IU/L |
|
| Glutamic pyruvic transaminase (GPT) | Mean | Standard Deviation | IU/L |
|
| Creatinine | Mean | Standard Deviation | mmol/L |
|
| Uric Acid | Mean | Standard Deviation | mmol/L |
|
| Area under the curve of glucose (AUCG) | Area under the curve of glucose was obtained using the trapezoidal integration. | Mean | Standard Deviation | mmol/L/min |
|
| Area under the curve of insulin (AUCI) | Area under the curve of insulin was obtained using the trapezoidal integration. | Mean | Standard Deviation | pmol/L/min |
|
| Total insulin secretion | Total insulin secretion was calculated with the Insulinogenic index (Δ ABC insulin / Δ ABC glucose). | Mean | Standard Deviation | Unitless |
|
| First phase of insulin secretion | Calculated by Stumvoll index [1283 + 1.829 · insulin 30 min (pmol/L) -138.7 · glucose 30 min (mmol/L) + 3.772 · insulin 0 min (pmol/L)] | Mean | Standard Deviation | Unitless |
|
| Insulin sensitivity | Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)] | Mean | Standard Deviation | Unitless |
|
|
|
|
| Primary | 2 Hours Plasma Glucose (2-h PG) | Subjects underwent a 2-h oral glucose tolerance test (2-h OGTT) by consuming 75-g of a dextrose load, and one sample was obtained 120 min after glucose administration. | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmol/L | Week 12. |
|
|
|
|
| Primary | Glycated Hemoglobin A1c (A1C) | Shows what a person's average blood glucose level was for the 2 to 3 months before the test high-performance. | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | Percentage of A1C | Week 12. |
|
|
|
|
| Primary | Total Insulin Secretion | After intervention. Total insulin secretion was calculated with the Insulinogenic index (Δ ABC insulin / Δ ABC glucose). | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | Unitless | Week 12. |
|
|
|
|
| Primary | First Phase of Insulin Secretion | After intervention with Stumvoll index | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | Unitless | Week 12. |
|
|
|
|
| Primary | Insulin Sensitivity | After intervention Matsuda Index | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | Unitless | Week 12. |
|
|
|
|
| Secondary | Area Under the Curve of Glucose | Area under the curve of glucose was obtained using the trapezoidal integration. | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmol/l/min | Week 12. |
|
|
|
| Secondary | Area Under the Curve of Insulin | Before and after intervention area under the curve of insulin | Posted | Mean | Standard Deviation | pmol/L/min | Week 12. |
|
|
|
|
| Secondary | Body Weight | The weight was measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | kg | Week 12. |
|
|
|
|
| Secondary | Body Mass Index | The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12 | Posted | Mean | Standard Deviation | kg/m^2 | Week 12. |
|
|
|
|
| Secondary | Waist Circumference (WC) | Waist circumference was evaluated at baseline and at week 12 with a flexible tape and the entered values reflects the waist circumference measure at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | cm | Week 12. |
|
|
|
|
| Secondary | Systolic Blood Pressure (SBP) | The Systolic Blood Pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmHg | Week 12. |
|
|
|
|
| Secondary | Diastolic Blood Plessure (DBP) | The Diastolic blood plessure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmHg | Week 12. |
|
|
|
|
| Secondary | Triglycerides (TG) | The triglycerides were evaluated at baseline and week 12 with enzymatic-colorimetric techniques and the entered values reflect the triglycerides level at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmol/L | Week 12. |
|
|
|
|
| Secondary | Total Cholesterol (TC) | The total cholesterol was estimated by standardized techniques at baseline and week 12 and the entered values reflect the total cholesterol level at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmol/L | Week 12. |
|
|
|
|
| Secondary | High-density Lipoprotein Cholesterol (HDL-C) | The HDL-C levels were evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the HDL-C level at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmol/L | Week 12. |
|
|
|
|
| Secondary | Low-density Lipoprotein Cholesterol (LDL-C) | The LDL-C levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the LDL-C levels at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmol/L | Week 12. |
|
|
|
|
| Secondary | Very-low Density Lipoprotein (VLDL) | The VLDL levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the c-LDL levels at week 12 | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmol/L | Week 12. |
|
|
|
|
| Secondary | Glutamic Pyruvic Transaminase (GPT) | Before and after intervention by spectrophotometry | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | IU/L | Week 12. |
|
|
|
|
| Secondary | Glutamic Oxaloacetic Transaminase (GOT) | Before and after intervention by spectrophotometry | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | IU/L | Week 12. |
|
|
|
|
| Secondary | Creatinine | The creatinine levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the uric acid levels at week 12 | Posted | Mean | Standard Deviation | mmol/L | Week 12. |
|
|
|
|
| Secondary | Uric Acid | The uric acid levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the creatinina levels at week 12. | 3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively. | Posted | Mean | Standard Deviation | mmol/l | Week 12. |
|
|
|
|
| 0 |
| 15 |
| 3 |
| 15 |
| EG001 | Chlorogenic Acid | 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days. Chlorogenic acid: Chologenic acid: 1200 mg per day for three months | 0 | 15 | 2 | 15 |
| Headacha | Nervous system disorders | ANY | Systematic Assessment |
|
| polyuria | Renal and urinary disorders | ANY | Systematic Assessment |
|
| abdominal pain | Gastrointestinal disorders | ANY | Systematic Assessment |
|
| abdominal distention | Gastrointestinal disorders | ANY | Systematic Assessment |
|
Not provided
Not provided
| D006946 | Hyperinsulinism |
| D003509 |
| Cyclohexanecarboxylic Acids |